Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Allergy Therapeutics raises £17mln ahead of key vaccine trials

Allergy Therapeutics raises £17mln ahead of key vaccine trials

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Nick Wykeman talked to Proactive about its latest results and the upcoming clinical trials for its peanut and grass pollen allergy vaccines.

The company also announced a £17mln funding round to pay for the trials and bolster its balance sheet.

#ProactiveInvestors #AllergyTherapeutics #aim #otc

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK